258.90
Schlusskurs vom Vortag:
$258.38
Offen:
$260.22
24-Stunden-Volumen:
376.02K
Relative Volume:
0.74
Marktkapitalisierung:
$10.34B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$42.23M
KGV:
244.25
EPS:
1.06
Netto-Cashflow:
$150.33M
1W Leistung:
-3.02%
1M Leistung:
-11.32%
6M Leistung:
+9.13%
1J Leistung:
+31.82%
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Vergleichen Sie PEN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PEN
Penumbra Inc
|
258.90 | 10.34B | 1.24B | 42.23M | 150.33M | 1.06 |
![]()
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-14 | Eingeleitet | BofA Securities | Buy |
2025-01-21 | Eingeleitet | UBS | Buy |
2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2024-09-18 | Eingeleitet | Stifel | Buy |
2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
2023-03-29 | Herabstufung | Needham | Buy → Hold |
2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
2022-10-12 | Eingeleitet | Jefferies | Buy |
2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
2022-09-09 | Hochstufung | Needham | Hold → Buy |
2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
2022-03-08 | Eingeleitet | Needham | Hold |
2021-09-16 | Eingeleitet | Truist | Buy |
2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
2020-09-29 | Eingeleitet | BTIG Research | Buy |
2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
2020-03-05 | Eingeleitet | Citigroup | Buy |
2019-06-13 | Bestätigt | BofA/Merrill | Buy |
2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-05-21 | Eingeleitet | William Blair | Outperform |
2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
2018-02-21 | Eingeleitet | William Blair | Outperform |
2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Insider Sell: Johanna Roberts Sells 600 Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra Introduces the Ruby® XL Systemthe Longest, Largest, and Softest Coil on the Market for Vascular Embolization - StreetInsider
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now - ACCESS Newswire
Penumbra Introduces the Ruby® Xl System - marketscreener.com
PEN Unveils Ruby XL System with FDA Clearance | PEN Stock News - GuruFocus
Penumbra announces FDA approval, launch of Ruby XL System - TipRanks
Just Launched: Penumbra's New Ruby XL System Delivers 40mm Coils Through Standard CathetersLargest in Market - Stock Titan
Penumbra’s EVP Johanna Roberts sells $154,903 in stock By Investing.com - Investing.com Canada
Transcript : Penumbra, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 09 - marketscreener.com
Transcript : Penumbra, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Penumbra Insider Sold Shares Worth $4,366,920, According to a Recent SEC Filing - marketscreener.com
Penumbra CEO Adam Elsesser sells $4.37 million in stock By Investing.com - Investing.com Canada
Penumbra CEO Adam Elsesser sells $4.37 million in stock - Investing.com Australia
Penumbra Amends Incorporation Certificate After Stockholder Vote - TipRanks
Managing Acute Limb Ischemia With Penumbra Lightning Bolt™ Technology - HMP Global Learning Network
Why Investors Shouldn't Be Surprised By Penumbra, Inc.'s (NYSE:PEN) P/S - simplywall.st
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report? - Yahoo Finance
Penumbra (NYSE:PEN) shareholders are still up 88% over 3 years despite pulling back 3.1% in the past week - Yahoo Finance
Penumbra, Inc. to Present at Upcoming Investor Conferences - Eastern Progress
Penumbra Rallies 35.9% in a Year: What's Driving the Stock? - sharewise
Penumbra, Inc. to Present at Upcoming Investor Conferences | PEN Stock News - GuruFocus
Blend Extra: Stroke Awareness Month And How Quick Action Can Save Lives - TMJ4 News
Insider Sell Alert: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Here's Why Penumbra (PEN) is a Strong Momentum Stock - Yahoo Finance
Penumbra EVP Johanna Roberts sells $268,697 in stock By Investing.com - Investing.com Nigeria
Penumbra EVP Johanna Roberts sells $268,697 in stock - Investing.com
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
Stroke Awareness Month: Quick Action Can Save Lives - ABC Action News
Transcript : Penumbra, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
PEN INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now - ACCESS Newswire
PEN Q1 Earnings Call: U.S. Thrombectomy Drives Outperformance as International Headwinds Persist - Yahoo Finance
Penumbra stock surges on approval hopes By Investing.com - Investing.com Canada
Should You Consider Adding Penumbra (PEN) To Your Portfolio? - Insider Monkey
Penumbra CFO Maggie Yuen sells $598,020 in common stock - Investing.com
3 Mid-Cap Medical Stocks Outperforming the Market - The Globe and Mail
Penumbra’s SWOT analysis: stock poised for growth amid innovation and challenges - Investing.com Australia
LAWSUIT FILED: Penumbra, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP - ACCESS Newswire
SHAREHOLDER ALERT: Penumbra, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm - ACCESS Newswire
Penumbra Inc.: Can Its Innovation & Product Pipeline Foster Long-Term Growth & Competitiveness? - Smartkarma
Penumbra, Inc. Reports First Quarter 2025 Financial Results - Eastern Progress
We Think You Can Look Beyond Penumbra's (NYSE:PEN) Lackluster Earnings - simplywall.st
Penumbra, Inc. to Present at the BofA Securities 2025 Health Car - GuruFocus
Exclusive: Penumbra Management Team Set for Key Presentation at BofA Healthcare Conference - Stock Titan
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):